Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage.

G M Petersen1, J Slack, Y Nakamura

  • 1Medical Genetics Birth Defects Center, Cedars-Sinai Medical Center, UCLA School of Medicine.

Gastroenterology
|June 1, 1991

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Screening Guidelines And Premorbid Diagnosis Of Familial Adenomatous Polyposis Using Linkage.

    • DNA testing for familial adenomatous polyposis (FAP) improves genetic diagnosis and counseling. Early genetic screening significantly reduces the risk of developing FAP by age 30.

    Area of Science:

    • Genetics
    • Oncology
    • Gastroenterology

    Background:

    • Familial adenomatous polyposis (FAP) is an inherited condition that significantly increases colorectal cancer risk.
    • Genetic linkage analysis using chromosome 5q21-22 restriction fragment-length polymorphisms (RFLPs) offers a method for premorbid diagnosis.

    Observation:

    • Two families underwent DNA diagnosis for FAP using linked RFLPs.
    • Analysis of polyposis registers revealed that individuals inheriting the FAP gene manifested polyps by age 34.
    • A 7.5-year average interval was observed between initial negative screening and FAP development in some relatives.

    Findings:

    • Linkage analysis combined with sigmoidoscopy data can reduce the a priori 50% risk of FAP in relatives to less than 0.5% by age 30.
    • This genetic testing refines risk assessment for at-risk individuals.

    Implications:

    • Improved diagnostic accuracy for FAP allows for more precise genetic counseling.
    • Screening guidelines can be optimized, offering longer intervals for individuals testing negative for the FAP gene, reducing patient anxiety and healthcare burden.

    Related Experiment Videos